Compare Sun Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs NOVARTIS - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA NOVARTIS SUN PHARMA/
NOVARTIS
 
P/E (TTM) x 24.6 831.5 3.0% View Chart
P/BV x 2.6 25.0 10.5% View Chart
Dividend Yield % 0.6 1.8 34.5%  

Financials

 SUN PHARMA   NOVARTIS
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
NOVARTIS
Mar-19
SUN PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs679980 69.3%   
Low Rs375600 62.5%   
Sales per share (Unadj.) Rs121.1198.7 61.0%  
Earnings per share (Unadj.) Rs13.421.0 63.8%  
Cash flow per share (Unadj.) Rs20.722.3 92.9%  
Dividends per share (Unadj.) Rs2.7510.00 27.5%  
Dividend yield (eoy) %0.51.3 41.2%  
Book value per share (Unadj.) Rs172.6307.5 56.1%  
Shares outstanding (eoy) m2,399.2624.69 9,717.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.44.0 109.4%   
Avg P/E ratio x39.437.7 104.6%  
P/CF ratio (eoy) x25.535.5 71.8%  
Price / Book Value ratio x3.12.6 118.9%  
Dividend payout %20.647.7 43.1%   
Avg Mkt Cap Rs m1,264,65019,508 6,482.9%   
No. of employees `00017.50.6 3,012.2%   
Total wages/salary Rs m59,6711,171 5,095.3%   
Avg. sales/employee Rs Th16,608.18,445.4 196.7%   
Avg. wages/employee Rs Th3,409.62,015.7 169.2%   
Avg. net profit/employee Rs Th1,833.8891.0 205.8%   
INCOME DATA
Net Sales Rs m290,6594,907 5,923.6%  
Other income Rs m10,255783 1,310.4%   
Total revenues Rs m300,9145,689 5,289.0%   
Gross profit Rs m63,076123 51,364.7%  
Depreciation Rs m17,53332 55,133.6%   
Interest Rs m5,55316 34,921.4%   
Profit before tax Rs m50,246858 5,858.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,009340 1,767.3%   
Profit after tax Rs m32,093518 6,199.2%  
Gross profit margin %21.72.5 867.1%  
Effective tax rate %12.039.6 30.2%   
Net profit margin %11.010.6 104.7%  
BALANCE SHEET DATA
Current assets Rs m310,6928,055 3,857.4%   
Current liabilities Rs m173,3961,850 9,372.3%   
Net working cap to sales %47.2126.4 37.4%  
Current ratio x1.84.4 41.2%  
Inventory Days Days9945 220.0%  
Debtors Days Days11234 329.0%  
Net fixed assets Rs m232,477150 155,191.5%   
Share capital Rs m2,399123 1,944.3%   
"Free" reserves Rs m411,6917,469 5,512.4%   
Net worth Rs m414,0917,592 5,454.4%   
Long term debt Rs m15,2260-   
Total assets Rs m646,9389,824 6,585.0%  
Interest coverage x10.054.9 18.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.40.5 90.0%   
Return on assets %5.85.4 107.1%  
Return on equity %7.86.8 113.7%  
Return on capital %10.211.5 88.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,02558 114,627.4%   
Fx outflow Rs m38,6101,326 2,911.1%   
Net fx Rs m27,415-1,269 -2,160.9%   
CASH FLOW
From Operations Rs m21,965-1,943 -1,130.6%  
From Investments Rs m-6,8132,742 -248.4%  
From Financial Activity Rs m-27,305-298 9,156.7%  
Net Cashflow Rs m-8,442501 -1,683.9%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.1 2.0 256.5%  
FIIs % 23.0 1.6 1,437.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 21.5 38.6%  
Shareholders   133,026 41,647 319.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms Over 600 Points; Nifty Trades Above 9,200 Mark(01:30 pm)

Share markets in India have extended early gains and are presently trading on a strong note, lifted by private banks and finance stocks.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

Protect Your Wealth from Fund Managers(Fast Profits Daily)

May 14, 2020

Do you know how much you are paying in fees to your mutual fund? In this video I'll share with you my views.

How Commodity Prices Tell You When Stocks Will Go Up(Fast Profits Daily)

May 20, 2020

Commodity prices often provide clues to big moves in stock markets. In today's video, I'll explain this link.

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

Why Buffet - and you - should study Quantum Liquid Fund(The Honest Truth)

May 14, 2020

Ajit Dayal on how Quantum Liquid Fund and Warren Buffett have similar investing styles.

More

Get Rich as the
Market Rebounds from Covid-19

Coronavirus Rebound
Get this special guide, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


May 27, 2020 03:35 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS